Core A: The Physics Core is responsible for providing and maintaining PDT laser sources, for in vivo and ex vivo light dosimetry, for quality assurance of light delivery systems, and for establishment of absolute light dosimetry standards traceable to NIST. It implements useful technologies to routine clinical application. The Physics Core is responsible for providing laser support and in vivo light dosimetry for all projects. It works with Project 1 to develop human clinical trials for treatment of pleural disease. The core supports maintenance and operation of the lasers housed in the 8th floor of the Smilow Center for Translational Research (SCTR 8W) that will be used for the cell and mouse PDT experiments included in Projects 2, 3 and 4. All of these illuminations will be performed through the services of the Animal/Pathology Core with assistance from the Physics Core as needed. In addition, the Physics Core will perform an annual on-site visit for dosimetry calibration at Roswell Park Cancer Institute (RPCI) and will remotely perform quarterly reviews of the light dosimetry data from RPCI via email submission. The Physics Core will develop techniques to improve PDT dosimetry for human clinical trials to achieve better uniformity of light fluence distribution. Determination of tissue optical properties, blood flow, sensitizer distribution, and tissue oxygenation for individual patients may prove to be important in providing individualized treatment planning and thus improving cancer treatment. The major components of the Physics Core can be summarized as follows: 1) to provide maintenance and operation of laser and light sources for PDT;2) performance of in vivo and ex vivo light dosimetry;3) measurement of absolute light dosimetry;4) support for light dosimetry at RPCI and 5) to perform explicit PDT dosimetry for tissue optical properties, drug concentration, and tissue oxygenation before, during, and after PDT.
Core A PDT dosimetry of light and drug concentration is critical for the pleural PDT clinical trials to be performed in the proposal. QA of the light delivery system, laser power standard, and dosimetry measurement equipment is essential for consistent outcome of PDT clinical trials.
|Davis 4th, Richard W; Snyder, Emma; Miller, Joann et al. (2018) Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy. Photochem Photobiol :|
|Cramer, Gwendolyn; Simone 2nd, Charles B; Busch, Theresa M et al. (2018) Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma. J Thorac Dis 10:S2565-S2573|
|Ong, Yi Hong; Padawer-Curry, Jonah; Finlay, Jarod C et al. (2018) Determination of optical properties, drug concentration, and tissue oxygenation in human pleural tissue before and after Photofrin-mediated photodynamic therapy. Proc SPIE Int Soc Opt Eng 10476:|
|Ong, Yi Hong; Kim, Michele M; Huang, Zheng et al. (2018) Reactive Oxygen Species Explicit Dosimetry (ROSED) of a Type 1 Photosensitizer. Proc SPIE Int Soc Opt Eng 10476:|
|Zhu, Timothy C; Kim, Michele M; Padawer, Jonah et al. (2018) Light Fluence Dosimetry in Lung-simulating Cavities. Proc SPIE Int Soc Opt Eng 10476:|
|Chandra, Abhishek; Wang, Luqiang; Young, Tiffany et al. (2018) Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis. FASEB J 32:52-62|
|Ong, Yi Hong; Finlay, Jarod C; Zhu, Timothy C (2018) Monte Carlo modelling of fluorescence in semi-infinite turbid media. Proc SPIE Int Soc Opt Eng 10492:|
|Yan, Lesan; Amirshaghaghi, Ahmad; Huang, Dennis et al. (2018) Protoporphyrin IX (PpIX)-Coated Superparamagnetic Iron Oxide Nanoparticle (SPION) Nanoclusters for Magnetic Resonance Imaging and Photodynamic Therapy. Adv Funct Mater 28:|
|Dimofte, Andreea; Finlay, Jarod; Ong, Yi Hong et al. (2018) A quality assurance program for clinical PDT. Proc SPIE Int Soc Opt Eng 10476:|
|Ahn, Peter H; Finlay, Jarod C; Gallagher-Colombo, Shannon M et al. (2018) Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy. Photodiagnosis Photodyn Ther 21:28-35|
Showing the most recent 10 out of 127 publications